Quick Answer — What is Hexarelin Acetate?
Hexarelin Acetate (zwany również Examorelin) is a synthetic 6-amino-acid growth hormone secretagogue (GHS): His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, with the bioactive acetate salt counterion. CAS 140703-51-1 (free peptide) / 171263-26-6 (acetate salt). MW 887.04 free / 947.07 g/mol as acetate. The most potent ghrelin mimetic in the GHRP-2 / GHRP-6 / Ipamorelin family — strongly activates GHSR-1a on pituitary somatotrophs and on cardiomyocytes (the latter via CD36 receptor for cardioprotective effects independent of GH release). Drives strong GH pulsatile release without acute hunger increase, but with documented cortisol and prolactin elevation at higher doses. For laboratory research use only. Synthetic peptide — not natural ghrelin.
📦 Każde zamówienie jest objęte naszą Reshipment Assurance Policy — jeśli Twoja przesyłka nie dotrze w ciągu 20 dni roboczych, wysyłamy ją ponownie.
| Specyfikacja | Szczegóły |
|---|---|
| Klasa związku | Synthetic 6-aa peptide growth hormone secretagogue (GHRP family); ghrelin mimetic; acetate salt |
| Nazwa chemiczna | Hexarelin Acetate (synonyms: Examorelin, EP-23905, MF6003) |
| Numer CAS | 140703-51-1 (free peptide); 171263-26-6 (acetate salt) |
| Sekwencja | L-His-D-2-methyl-Trp-L-Ala-L-Trp-D-Phe-L-Lys-NH2 (6 amino acids; D-2-Me-Trp at position 2 and D-Phe at position 5 confer proteolytic stability and receptor selectivity; C-terminal amide) |
| Molecular Formula / MW | C47H58N12O6 (free peptide, MW 887.04 g/mol); + C2H4O2 acetate counterion (acetate salt, MW 947.07 g/mol) |
| Mechanizm | Dual-receptor pharmacology. (1) Primary: agonist at GHSR-1a (growth-hormone-secretagogue receptor type 1a, the ghrelin receptor) on pituitary somatotrophs — drives strong pulsatile GH release via Gq-PLC-IP3-Ca2+ signalling; also engages GHSR on arcuate-nucleus neurons. (2) Secondary: binds CD36 (a scavenger receptor) on cardiomyocytes, vascular endothelium, and macrophages — produces cardioprotective effects in ischaemia-reperfusion models independent of GH release. The dual mechanism is unique to Hexarelin among the GHRP family. |
| Potency vs Family | Most potent GH-releasing peptide in the GHRP-2 / GHRP-6 / Hexarelin / Ipamorelin family on a per-mg basis — but with corresponding cortisol and prolactin elevation at higher doses (in contrast to Ipamorelina, which produces clean GH-only release). |
| Postać | Lyophilized white-to-off-white powder; single-use research vials |
| Czystość | ≥99% (zweryfikowane HPLC, COA na życzenie) |
| Przechowywanie | Lyophilized: 2–8 °C short-term; −20 °C long-term (≥36 months). Reconstituted: 2–8 °C, use within 30 days. Avoid repeated freeze-thaw. |
| Do celów badawczych | For laboratory research use only. Not for human or veterinary diagnostic or therapeutic use. Hexarelin / Examorelin is on the WADA Prohibited List (class S2, Peptide Hormones and Growth Factors) and is prohibited at all times in athletic contexts. |
Mechanism of Action — Dual GHSR-1a + CD36 Pharmacology
Hexarelin is unique among the GHRP family in having well-documented activity at two mechanistically distinct receptors:
- GHSR-1a agonism (primary GH-releasing mechanism) — Hexarelin binds the ghrelin receptor (GHSR-1a, a Gq-coupled GPCR) on pituitary somatotrophs with sub-nanomolar affinity. Receptor activation drives PLC → IP3 → Ca2+ release, triggering GH secretory granule exocytosis. The D-2-Me-Trp at position 2 and D-Phe at position 5 confer high resistance to proteolytic degradation, extending the plasma half-life vs natural ghrelin.
- CD36 binding (secondary cardioprotective mechanism) — Hexarelin (unlike Ipamorelin or GHRP-6 to the same degree) binds CD36 — a scavenger receptor on cardiomyocytes, vascular endothelium, and macrophages. Published research (Bodart et al. 2002, others) has demonstrated direct cardioprotective effects in ischaemia-reperfusion injury models that are independent of growth hormone — the CD36-binding mechanism preserves cardiac contractility, reduces post-ischaemic ventricular dysfunction, and modulates macrophage activation.
- GH-axis downstream consequences — Like all GHRPs, Hexarelin’s GH-releasing activity drives downstream IGF-1 production, increased lipolysis, increased lean mass, and improved nitrogen balance in published in-vivo work. Effects largely mirror the broader GH-axis pharmacology.
- Tachyphylaxis with chronic dosing — Sustained high-dose Hexarelin produces GHSR-1a desensitization (tachyphylaxis), reducing GH-releasing potency over 4–6 weeks of continuous administration. Published research uses pulsed dosing protocols to mitigate this.
- Cortisol and prolactin elevation — At higher doses Hexarelin elevates serum cortisol and prolactin alongside GH (mirroring GHRP-2 and GHRP-6 in this respect). For research protocols where clean GH-only release is needed, Ipamorelina is the preferred selective alternative.
Opublikowane zastosowania badawcze
- GHRP / GH-secretagogue pharmacology — most potent GHRP reference compound on a per-mg basis
- GHSR-1a receptor pharmacology — canonical research tool alongside ghrelin and ipamorelin
- Cardioprotection research (CD36-dependent) — unique among the GHRP family for documented direct cardiac effects in ischaemia-reperfusion models
- Growth-hormone axis research — drives strong endogenous GH pulse without injecting exogenous hGH
- Body-composition research — used in published rodent work alongside GHRH analogues for lean-mass / fat-mass dissection
- Tachyphylaxis and GHSR-1a desensitization research — well-documented tachyphylaxis profile makes it a useful tool for receptor-desensitization pharmacology
For broader context see Ipamorelina (clean GH-only secretagogue — no cortisol/prolactin), Octan GHRP-2 (sibling GHS), Octan GHRP-6 (sibling GHS), CJC-1295 z DAC (GHRH analogue, commonly stacked), Sermorelina (GHRH 1-29).
Dostępne mocowania
| Mocowanie fiolki | Rozmiary opakowań |
|---|---|
| 2 mg — entry research protocols, dose-titration work | 10 lub 20 fiolek |
| 5 mg — standard research protocols, multi-cohort sample sizes; lowest per-mg cost | 10 lub 20 fiolek |
How It Compares — Hexarelin vs Ipamorelin
Ipamorelina is the cleanest GH-only secretagogue in this family — strong GH release with no cortisol or prolactin elevation. Hexarelin is the most potent in the family on a per-mg basis but elevates cortisol and prolactin at higher doses. Hexarelin also has the unique CD36-binding cardioprotective mechanism. Researchers choose Hexarelin for maximum GH-releasing potency or for the CD36 axis specifically; Ipamorelin for clean isolated GH-axis research where avoiding cortisol / prolactin confounders matters.
| Kryterium | Hexarelin | Ipamorelina |
|---|---|---|
| MW | 887 / 947 (acetate) | 711.85 |
| GH-release potency | Highest in family (per mg) | Strong but less potent than Hexarelin |
| Cortisol / prolactin | Elevated at higher doses | No documented elevation — clean |
| CD36 binding | Yes — cardioprotective | Minimal / not documented |
| Najlepsze dla | Max-potency GH research, cardioprotection | Clean GH-only research, no-confounder protocols |
Przechowywanie i rekonstytucja
Store lyophilized vials at 2–8 °C; freeze unopened vials at −20 °C for long-term storage. Reconstitute with bacteriostatic water (1.0 mL per 2 mg vial → 2 mg/mL; 1.0 mL per 5 mg vial → 5 mg/mL). Swirl gently to dissolve. Store reconstituted vials at 2–8 °C, use within 30 days. Protect from light. Avoid repeated freeze-thaw cycles.
FAQ
How is Hexarelin different from GHRP-2 and GHRP-6?
All three are 6-amino-acid synthetic GH-releasing peptides in the same family. Hexarelin is the most potent per-mg, but also elevates cortisol/prolactin more than GHRP-2 and less than GHRP-6. Hexarelin uniquely binds CD36 for cardioprotective effects not seen with GHRP-2 or GHRP-6.
What is the typical research dose?
Rodent in-vivo protocols typically use 50–200 µg/kg SC, 1–3×/day. In-vitro pituitary culture protocols use nanomolar concentrations. Published human research has used 1–2 mg SC per dose.
What is the WADA status?
Hexarelin (Examorelin) is on the WADA Prohibited List under class S2 (Peptide Hormones, Growth Factors). Prohibited at all times in athletic contexts.
Can Hexarelin be combined with CJC-1295 or other GHRH analogues?
Yes — Hexarelin (GHS) + CJC-1295 (GHRH analogue) is the canonical “GHRP + GHRH” stacking protocol that produces synergistic GH release through engagement of two complementary pituitary pathways. Sermorelin and Tesamorelin are alternative GHRH partners.
Other Research Peptides for Growth-Hormone Axis Research
- Ipamorelina — Clean GH-only secretagogue — no cortisol/prolactin elevation
- Octan GHRP-2 — Sibling GHRP family member
- Octan GHRP-6 — Sibling GHRP family member (also increases hunger)
- CJC-1295 z DAC — GHRH analogue — canonical stacking partner
- Sermorelina — GHRH 1-29 analogue — alternative GHRH partner
- BAC Water (Woda bakteriostatyczna) — Wymagany do rekonstytucji każdej liofilizowanej fiolki — sterylny rozcieńczalnik z 0,9% benzylowym alkoholem jako środkiem konserwującym

























Opinie
Nie ma jeszcze opinii